AR and prostate carcinoma: Pyrvinium pamoate was also found to act as a non-competitive androgen receptor (AR) inhibitor; PP inhibited endogenous AR activity in two prostate cancer cell lines, LANCaP and LAPC4, and reduced the expression of several androgen-responsive genes in LANCaP cells (Jones et al., 2009).